Israel will begin offering a fourth dose of COVID-19 vaccine

Israel plans to begin offering certain people a fourth dose of COVID-19 vaccination in an effort to combat the spread of omicron and other variants.

A Health Ministry expert panel said Tuesday that it recommends the additional dose to individuals 60 and older, the immunocompromised and healthcare workers. Those eligible should wait at least four months after receiving their third dose, Reuters reported Dec. 22.

"We are seeing a waning of protection against omicron infection. This wave is growing in surprisingly high numbers... More than 80% of the panel supported this measure," Arnon Shahar, a doctor on the expert panel, told Israel's Army Radio.

Additionally, the panel recommends administering a third dose three months after a second shot, down from the country’s current five month standard.

Health Ministry Director-General Nachman Ash still must approve these new suggestions, Reuters noted, and there’s no timetable for a decision.

Israel’s initial vaccine rollout outpaced that of most other nations and 62% of its population has now received at least two doses. Officials recently took additional actions against the new variant, banning foreigners from entering the country and reducing office attendance by 50% for public employees.

Read the full report below.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.